|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
310,240,000 |
Market
Cap: |
6.83(B) |
Last
Volume: |
1,350,945 |
Avg
Vol: |
2,431,686 |
52
Week Range: |
$18.78 - $24.13 |
|
Level
I Sector: |
Industrials |
Level
II Sector: |
Diversified Services |
Level
III Sector: |
Research Services |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : 17.5 |
Insider 6 Months : 18.9 |
Insider 3/6 Months : 36.8 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
425,000 |
615,000 |
735,409 |
735,409 |
Total Buy Value |
$8,733,955 |
$12,666,689 |
$15,268,727 |
$15,268,727 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
2 |
3 |
4 |
4 |
Total Shares Sold |
88,818 |
210,838 |
601,659 |
1,021,249 |
Total Sell Value |
$1,938,121 |
$4,689,450 |
$12,908,109 |
$20,266,173 |
Total People Sold |
5 |
7 |
9 |
12 |
Total Sell Transactions |
6 |
9 |
17 |
28 |
End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Garber Alan M |
Director |
|
2020-02-14 |
4 |
AS |
$21.02 |
$262,750 |
D/D |
(12,500) |
48,829 |
|
18% |
|
Morrissey Michael M |
President and CEO |
|
2020-02-13 |
4 |
AS |
$20.11 |
$502,750 |
D/D |
(25,000) |
85,985 |
|
17% |
|
Morrissey Michael M |
President and CEO |
|
2020-02-13 |
4 |
OE |
$5.51 |
$137,750 |
D/D |
25,000 |
110,985 |
|
- |
|
Scangos George A |
Director |
|
2020-02-12 |
4 |
AS |
$20.02 |
$420,420 |
D/D |
(21,000) |
1,013,031 |
|
19% |
|
Scangos George A |
Director |
|
2020-02-11 |
4 |
AS |
$20.14 |
$80,560 |
D/D |
(4,000) |
1,034,031 |
|
25% |
|
Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
|
2020-02-07 |
4 |
AS |
$18.37 |
$918,500 |
D/D |
(50,000) |
325,122 |
|
18% |
|
Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
|
2020-02-07 |
4 |
OE |
$5.51 |
$275,500 |
D/D |
50,000 |
375,122 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2020-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
224,287 |
634,166 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2020-01-29 |
4 |
AS |
$17.87 |
$446,750 |
D/D |
(25,000) |
85,985 |
|
27% |
|
Morrissey Michael M |
President and CEO |
|
2020-01-29 |
4 |
OE |
$5.51 |
$137,750 |
D/D |
25,000 |
110,985 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2020-01-23 |
4 |
AS |
$19.41 |
$485,250 |
D/D |
(25,000) |
85,985 |
|
18% |
|
Morrissey Michael M |
President and CEO |
|
2020-01-23 |
4 |
OE |
$5.51 |
$137,750 |
D/D |
25,000 |
110,985 |
|
- |
|
Scangos George A |
Director |
|
2020-01-22 |
4 |
AS |
$19.75 |
$493,750 |
D/D |
(25,000) |
1,038,031 |
|
23% |
|
Morrissey Michael M |
President and CEO |
|
2020-01-16 |
4 |
AS |
$20.33 |
$508,250 |
D/D |
(25,000) |
85,985 |
|
19% |
|
Morrissey Michael M |
President and CEO |
|
2020-01-16 |
4 |
OE |
$5.51 |
$137,750 |
D/D |
25,000 |
110,985 |
|
- |
|
Scangos George A |
Director |
|
2020-01-15 |
4 |
AS |
$20.39 |
$509,750 |
D/D |
(25,000) |
1,063,031 |
|
19% |
|
Marchesi Vincent T |
Director |
|
2020-01-15 |
4 |
AS |
$20.01 |
$1,234,277 |
D/D |
(61,683) |
82,484 |
|
19% |
|
Morrissey Michael M |
President and CEO |
|
2020-01-08 |
4 |
AS |
$18.85 |
$471,250 |
D/D |
(25,000) |
85,985 |
|
40% |
|
Morrissey Michael M |
President and CEO |
|
2020-01-08 |
4 |
OE |
$5.51 |
$137,750 |
D/D |
25,000 |
110,985 |
|
- |
|
Garber Alan M |
Director |
|
2020-01-07 |
4 |
AS |
$18.01 |
$1,566,078 |
D/D |
(86,956) |
61,329 |
|
51% |
|
Garber Alan M |
Director |
|
2020-01-07 |
4 |
OE |
$4.58 |
$468,884 |
D/D |
86,956 |
148,285 |
|
- |
|
Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
|
2020-01-07 |
4 |
AS |
$17.96 |
$898,000 |
D/D |
(50,000) |
325,122 |
|
51% |
|
Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
|
2020-01-07 |
4 |
OE |
$5.51 |
$275,500 |
D/D |
50,000 |
375,122 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2020-01-02 |
4 |
AS |
$17.49 |
$437,250 |
D/D |
(25,000) |
85,985 |
|
55% |
|
Morrissey Michael M |
President and CEO |
|
2020-01-02 |
4 |
OE |
$5.51 |
$137,750 |
D/D |
25,000 |
110,985 |
|
- |
|
1438 Records found
|
|
Page 22 of 58 |
|
|